Research-Grade peptide Products

A small-molecule NNMT inhibitor (technically not a peptide) grouped with peptides in fat-loss contexts, investigated in preclinical obesity and muscle-aging models.

N-acetyl-seryl-aspartyl-lysyl-proline — a naturally occurring anti-fibrotic tetrapeptide derived from the N-terminus of thymosin beta-4, regulated by ACE and studied for cardiac, renal, and pulmonary fibrosis.

A synthetic hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg) that modulates enkephalin signaling at the neuromuscular junction to reduce muscle contraction intensity, functioning as a complementary mechanism to Argireline for topical wrinkle reduction.

A biomimetic signaling peptide and key active ingredient in Capixyl hair loss treatments, proposed to counteract DHT-driven follicle miniaturization and reduce perifollicular inflammation.

A seven-amino-acid fragment of adrenocorticotropic hormone with cognitive-enhancing properties independent of adrenal stimulation, studied for attention, memory, and learning enhancement in both animal and human trials.

An experimental chimeric peptide that targets prohibitin on adipose vasculature, inducing apoptosis of blood vessels feeding white fat tissue. Studied in obese primates with dramatic fat reduction but no human trials to date.

A modified analog of BPC-157 incorporating alpha-aminoisobutyric acid (Aib) substitutions to enhance proteolytic stability and extend biological half-life while preserving cytoprotective activity.

A stable dipeptide form of glutamine used in clinical nutrition for gut barrier integrity, immune support, and post-surgical recovery — solving glutamine's instability problem.

A next-generation biomimetic lipopeptide from Sederma's Matrixyl family that targets age-related dermal matrix architecture changes by upregulating TGF-beta signaling, fibrillin-1, and elastic fiber network components — addressing deep structural skin aging beyond collagen alone.

A small-molecule anti-inflammatory agent repurposed for metabolic research, studied as an IKKε/TBK1 inhibitor that may reverse obesity-associated insulin resistance.

A counter-regulatory heptapeptide of the renin-angiotensin system that opposes the vasoconstrictive and pro-inflammatory effects of angiotensin II through the Mas receptor, with cardioprotective, anti-fibrotic, and anti-inflammatory properties.

A 16-amino-acid fragment of the C-terminus of human growth hormone (residues 176–191), marketed for fat-loss lipolytic activity but weak in controlled human trials.

An endogenous peptide ligand for the APJ receptor (apelin receptor) with potent cardiovascular, angiogenic, and fluid homeostasis functions, studied as a potential therapeutic in heart failure and metabolic disease.

A biotinylated derivative of the copper-binding tripeptide GHK, combining the collagen-stimulating and wound-healing properties of GHK-Cu with biotin's keratin-supporting activity for enhanced hair and nail applications.

A 15-amino-acid peptide fragment derived from gastric juice protein BPC, studied extensively in animal models for tissue healing and gut integrity.

An endogenous dipeptide (beta-alanine-L-histidine) with potent anti-glycation, antioxidant, and pH-buffering properties, concentrated in muscle and brain tissue, studied extensively for anti-aging and neuroprotective applications.

A tripeptide bioregulator (Ala-Glu-Asp) targeting cartilage and musculoskeletal tissue, studied for joint protection, cartilage regeneration, and osteoarthritis prevention in aging.

A 21-amino-acid endogenous peptide derived from chromogranin A that inhibits catecholamine release via nicotinic acetylcholine receptor antagonism, with cardiovascular protective, antimicrobial, and metabolic regulatory properties under active investigation for hypertension and heart failure.

Calcitonin gene-related peptide, the most potent endogenous vasodilator known, with a central role in migraine pathophysiology and emerging significance in wound healing and cardiovascular protection.

An investigational peptide-chrysin conjugate combining the flavonoid aromatase inhibitor chrysin with a bioactive peptide carrier to enhance bioavailability and target estrogen metabolism modulation in research contexts.

A long-acting GHRH (1-29) analog with a Drug Affinity Complex that binds serum albumin, giving an estimated half-life of about 6–8 days and sustained GH and IGF-1 increases in healthy adults; research-only in the US.

The most widely used GHRH + GHRP stack — CJC-1295 extends GHRH half-life while Ipamorelin selectively amplifies GH pulses without disturbing cortisol or prolactin.

A tetrasubstituted GHRH (1-29) analog — CJC-1295 without the albumin-binding Drug Affinity Complex, often sold as Modified GRF 1-29; it has very little published human data and is research-only in the US.

A tetrapeptide bioregulator (Ala-Glu-Asp-Gly) studied for cerebral cortex regulation, neuroprotection after ischemia, and potential cognitive benefits in aging populations.

A neuropeptide structurally related to somatostatin that promotes slow-wave sleep, modulates cortical activity, and exerts potent anti-inflammatory effects through both somatostatin-shared and cortistatin-specific receptor pathways.

A hexapeptide analog of angiotensin IV that crosses the blood-brain barrier and promotes synaptogenesis via hepatocyte growth factor (HGF) signaling — studied for cognitive enhancement and neurodegenerative disease.

A nonapeptide first studied in rabbits in the 1970s for its effect on delta-wave sleep. Small 1980s-1990s human trials gave mixed results; in the US it is a research-only compound.

A once-weekly, cAMP-biased GLP-1 receptor agonist engineered to preferentially signal through the cAMP pathway. Investigated for type 2 diabetes and obesity, with both subcutaneous and oral formulations under development.

A once-weekly, exendin-based GLP-1 receptor agonist built on an antibody Fc fusion scaffold. Notable for the AMPLITUDE-O cardiovascular outcomes trial, which showed reductions in major cardiovascular and renal events in high-risk type 2 diabetes.

A synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on pineal extract Epithalamin — studied by Russian researchers for telomerase, circadian, and longevity endpoints.

Alternate spelling of Epitalon, the synthetic tetrapeptide Ala-Glu-Asp-Gly (AEDG). Research-only: not approved by the FDA, with telomerase data from cell culture and human outcome data mostly from the Khavinson group's studies of the related pineal extract Epithalamin.

A 344-amino-acid glycoprotein that antagonizes myostatin and activin A — the primary endogenous brake on skeletal muscle growth — studied for muscle wasting and gene therapy applications.

A D-retro-inverso peptide that disrupts FOXO4-p53 interactions in senescent cells, triggering selective apoptosis. The first peptide-based senolytic — published in Cell (2017) with striking mouse healthspan data.

The base copper-binding tripeptide (Gly-His-Lys) found in human plasma and tissues — a precursor to GHK-Cu with intrinsic bioactivity in wound healing, gene modulation, and anti-inflammatory signaling.

A synthetic growth-hormone-releasing hexapeptide and ghrelin-receptor agonist that produces strong GH release in humans but also raises prolactin, ACTH and cortisol; research-only in the US.

The original synthetic growth-hormone-releasing hexapeptide (His-DTrp-Ala-Trp-DPhe-Lys-NH2): a potent GH secretagogue in humans that also raises prolactin and cortisol and stimulates eating in animal studies; research-only in the US.

A long-acting GLP-2 receptor analog engineered for less-frequent dosing than teduglutide. Investigated for short bowel syndrome, it stimulates intestinal mucosal growth and absorption with a once- or twice-weekly regimen.

The master intracellular antioxidant tripeptide (gamma-L-glutamyl-L-cysteinyl-glycine) that serves as the primary cellular defense against oxidative stress, xenobiotic toxicity, and redox imbalance across virtually all human tissues.

A naturally occurring tripeptide cleaved from the N-terminus of IGF-1 in the brain, studied as a neuroprotective agent in stroke and neurodegeneration models.

A synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH) — used diagnostically to assess pituitary gonadotroph reserve and therapeutically to stimulate LH/FSH release.

A synthetic analog of endogenous GnRH (gonadotropin-releasing hormone) used clinically to evaluate pituitary gonadotropin reserve and investigated for fertility and hormonal optimization protocols.

A potent synthetic GH-releasing hexapeptide that also binds the cardiac receptor CD36; it showed GH-independent cardioprotection in rat ischemia models and acute effects on heart function in small human studies.

A modified fragment of human growth hormone (amino acids 176-191) that retains GH's lipolytic activity without its growth-promoting or diabetogenic effects. The most targeted fat-loss peptide in research use.

A 24-amino-acid mitochondrial-derived peptide (MDP) with cytoprotective, anti-apoptotic, and neuroprotective activity. Encoded within the mitochondrial genome, humanin represents a new class of retrograde signaling molecules.

An oral, non-peptide growth hormone secretagogue that mimics ghrelin at the GHSR-1a receptor — produces sustained GH and IGF-1 elevation without injections. Extensively studied in human trials.

A long-acting analog of insulin-like growth factor 1 with substitutions that reduce IGF-binding-protein affinity, extending half-life and increasing free IGF-1 activity.

The most selective GHRP (growth-hormone-releasing peptide) — amplifies GH pulses via ghrelin/GHSR receptor without meaningful cortisol, prolactin, or aldosterone crosstalk.

An exercise-induced myokine cleaved from fibronectin type III domain-containing protein 5 (FNDC5) that mediates metabolic benefits of physical activity including white-to-brown fat conversion and improved glucose homeostasis.

A copper-binding tripeptide (Lys-His-Lys) that chelates Cu2+ ions to promote collagen synthesis, wound healing, and hair follicle stimulation as an alternative to GHK-Cu.

A 10-amino-acid fragment of the kisspeptin neuropeptide, the minimal sequence with full bioactivity at the kisspeptin receptor. It stimulates the hypothalamic GnRH system and has been studied in small human physiology studies of reproductive hormone release. Research-only.

The full-length 54-amino-acid product of the KISS1 gene — the master upstream regulator of the hypothalamic GnRH pulse generator, central to puberty onset, reproductive cyclicity, and fertility.

A C-terminal tripeptide fragment of alpha-MSH with anti-inflammatory activity in cell and mouse colitis models, studied for NF-κB inhibition without alpha-MSH's pigmentary effects.

A cationic antimicrobial peptide derived from the N-terminal region of lactoferrin by pepsin digestion, possessing broad-spectrum antimicrobial, antifungal, antiviral, and immunomodulatory properties.

A tetrapeptide bioregulator (Lys-Glu-Asp-Ala) targeting liver tissue, studied for hepatoprotection, chromatin decondensation, and restoration of liver function in aging models.

The only human cathelicidin antimicrobial peptide (37 amino acids), with antibacterial, antifungal and antiviral activity plus immunomodulatory, anti-biofilm and wound-healing effects in laboratory studies.

A 43-amino-acid soy-derived peptide with epigenetic anti-cancer properties that inhibits histone acetyltransferase activity and modulates innate immunity through RGD integrin binding.

A synthetic cyclic analog of α-MSH that acts non-selectively on melanocortin receptors, causing skin tanning and penile erections. The parent molecule of PT-141; unapproved and research-only in the US.

Mechano growth factor (MGF) names an IGF-1 splice variant that muscle expresses after mechanical loading or damage, and a synthetic 24-amino-acid peptide copied from its unique C-terminal E domain. Cell studies disagree on whether the peptide does anything; there are no human trials, and it is an unapproved research chemical prohibited in sport.

A 16-amino-acid peptide encoded in the mitochondrial 12S rRNA — investigated as a metabolic regulator of AMPK signaling and insulin sensitivity.

An N-acetylated, amidated analog of Selank with improved metabolic stability and enhanced CNS bioavailability — studied for anxiolytic and nootropic effects.

An off-label, ultra-low-dose application of the opioid antagonist naltrexone that paradoxically upregulates endogenous endorphin and enkephalin production, widely explored for autoimmune modulation and chronic inflammation.

An 82-amino-acid anorexigenic peptide derived from nucleobindin-2 (NUCB2) that suppresses appetite through hypothalamic signaling and crosses the blood-brain barrier, studied for potential anti-obesity applications.

A synthetic MC1R antagonist peptide used in cosmetic skin-lightening formulations to inhibit melanin synthesis and transfer from melanocytes to keratinocytes, reducing hyperpigmentation.

A nine-amino-acid neuropeptide produced in the hypothalamus. The 'bonding hormone' has well-established roles in labor, lactation, and social cognition, with emerging research in autism, PTSD, and metabolic regulation.

A small peptide fragment derived from ciliary neurotrophic factor (CNTF) that promotes neurogenesis and enhances cognitive function in animal models by crossing the blood-brain barrier.

A lipidated derivative of the copper-binding tripeptide GHK, designed for enhanced skin penetration in topical anti-aging formulations.

The pentapeptide form of Matrixyl (palmitoyl pentapeptide-4) — Pal-Lys-Thr-Thr-Lys-Ser — a type I collagen fragment mimetic that is one of the most clinically validated topical peptides for wrinkle reduction and skin firmness.

A lipopeptide consisting of palmitic acid conjugated to a dipeptide sequence (Lys-Val) that stimulates collagen synthesis and extracellular matrix remodeling for anti-aging skin applications.

The original Matrixyl peptide — a lipopeptide that mimics the collagen I pro-peptide fragment to stimulate fibroblast production of collagens I, III, IV, fibronectin, and hyaluronic acid. One of the most studied anti-wrinkle cosmetic peptides.

A short synthetic peptide bioregulator (tetrapeptide) developed within the Khavinson bioregulator framework and proposed to support pancreatic tissue function. Evidence is limited and derived largely from Russian preclinical and small clinical studies.

PE-22-28 is a seven-amino-acid fragment of spadin that blocks the TREK-1 potassium channel. In mouse studies from one research group it had antidepressant-like effects within days; it has never been tested in humans and is an unapproved research chemical.

PEGylated Mechano Growth Factor — a splice variant of IGF-1 modified with polyethylene glycol for extended half-life. Studied for its role in muscle satellite cell activation and tissue repair.

A polyethylene glycol-conjugated variant of BPC-157 engineered for extended half-life and reduced injection frequency while retaining the parent peptide's tissue-healing properties.

A polyethylene glycol-conjugated form of thymosin alpha-1 designed to extend circulating half-life from hours to days, reducing injection frequency while preserving immunomodulatory potency.

A synthetic tripeptide (Glu-Asp-Arg, EDR) from the Khavinson bioregulator family, studied for neuroprotection mainly in cell and rodent experiments. Research-only and not FDA-approved; human data are limited to small Russian studies.

A synthetic heptapeptide analog of the endogenous peptide tuftsin, studied in Russia as an anxiolytic. Human data come from small Russian trials; in the US it is a research-only compound.

A synthetic heptapeptide analog of ACTH(4-10) developed in Russia as a nootropic and studied there in ischemic stroke. Human data are small Russian studies; in the US it is a research-only compound.

The first synthetic GHRH analog approved for clinical use — GHRH (1-29) NH₂, the minimum active sequence. Shorter-acting than tesamorelin or CJC-1295.

A heptapeptide cosmetic neuropeptide that inhibits SNARE complex formation at the neuromuscular junction to reduce facial muscle contractions and dynamic wrinkles, functioning as a topical botulinum toxin alternative.

A synthetic octapeptide that mimics the N-terminal of SNAP-25, reducing neuromuscular signaling to facial muscles. The 'topical Botox' of peptide skincare — with more modest results.

A cell-permeable tetrapeptide that targets the inner mitochondrial membrane, stabilizing cardiolipin and improving electron transport chain efficiency — in late-stage clinical trials for mitochondrial and cardiac diseases.

A polypeptide complex extracted from calf thymus, used clinically in Russia for immune restoration and studied for anti-aging effects including mortality reduction in elderly cohorts.

A cell-permeable autophagy-inducing peptide derived from a key region of the Beclin 1 protein fused to the HIV-1 Tat transduction domain, engineered to potently activate cellular self-cleaning pathways.

Synthetic peptide based on the actin-binding region of Thymosin β4, a protein studied for cell migration and tissue repair in skin, cornea, and heart models.

A triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for neurodegenerative diseases, repurposed for obesity after demonstrating significant weight loss in clinical trials.

A thymic peptide bioregulator developed by the St. Petersburg Institute of Bioregulation and Gerontology, studied in Russian clinical cohorts for immune reconstitution and longevity.

A synthetic pentapeptide (Arg-Lys-Asp-Val-Tyr) corresponding to residues 32-36 of thymopoietin, used clinically in some countries for immune modulation in immunodeficiency and autoimmune conditions.

A synthetic pentapeptide (Arg-Lys-Asp-Val-Tyr) representing the active site of the 49-amino-acid thymic hormone thymopoietin, used clinically in several countries for T-cell immunomodulation in immunodeficiency, autoimmune conditions, and as adjunct cancer therapy.

A lesser-studied member of the beta-thymosin family with documented angiogenic and tumor-associated properties, investigated as both a cancer biomarker and a potential modulator of vascular growth.

A 43-amino acid peptide and the primary intracellular G-actin sequestering protein. TB-500 is a synthetic fragment of Thymosin Beta-4's active site — this is the full-length parent molecule with broader tissue repair and anti-inflammatory evidence.

The biologically active zinc-bound form of thymulin (facteur thymique serique), a nonapeptide secreted by thymic epithelial cells that requires zinc chelation for immunomodulatory activity.

A zinc-dependent nonapeptide hormone made by thymic epithelial cells that supports T-cell differentiation. Thymulin is not an approved medicine; therapeutic data are almost entirely from animal studies.

A tripeptide bioregulator (Lys-Glu-Asp) targeting vascular endothelium, studied for cardiovascular protection, endothelial function restoration, and atherosclerosis prevention in aging.

A dipeptide bioregulator (Lys-Glu) derived from thymus tissue, studied for immune system regulation, thymic regeneration, and anti-aging effects in elderly populations.

A 28-amino-acid neuropeptide with broad immunomodulatory, vasodilatory, and neuroprotective activity. Studied in CIRS (chronic inflammatory response syndrome), pulmonary hypertension, and gut motility disorders.